BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 26864161)

  • 1. Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma.
    Bernuzzi F; Marabita F; Lleo A; Carbone M; Mirolo M; Marzioni M; Alpini G; Alvaro D; Boberg KM; Locati M; Torzilli G; Rimassa L; Piscaglia F; He XS; Bowlus CL; Yang GX; Gershwin ME; Invernizzi P
    Clin Exp Immunol; 2016 Jul; 185(1):61-71. PubMed ID: 26864161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNAs in Serum and Bile of Patients with Primary Sclerosing Cholangitis and/or Cholangiocarcinoma.
    Voigtländer T; Gupta SK; Thum S; Fendrich J; Manns MP; Lankisch TO; Thum T
    PLoS One; 2015; 10(10):e0139305. PubMed ID: 26431155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis.
    Lankisch TO; Metzger J; Negm AA; Vosskuhl K; Schiffer E; Siwy J; Weismüller TJ; Schneider AS; Thedieck K; Baumeister R; Zürbig P; Weissinger EM; Manns MP; Mischak H; Wedemeyer J
    Hepatology; 2011 Mar; 53(3):875-84. PubMed ID: 21374660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profiling of downregulated blood-circulating miR-150-5p as a novel tumor marker for cholangiocarcinoma.
    Wu X; Xia M; Chen D; Wu F; Lv Z; Zhan Q; Jiao Y; Wang W; Chen G; An F
    Tumour Biol; 2016 Nov; 37(11):15019-15029. PubMed ID: 27658773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis.
    Banales JM; Iñarrairaegui M; Arbelaiz A; Milkiewicz P; Muntané J; Muñoz-Bellvis L; La Casta A; Gonzalez LM; Arretxe E; Alonso C; Martínez-Arranz I; Lapitz A; Santos-Laso A; Avila MA; Martínez-Chantar ML; Bujanda L; Marin JJG; Sangro B; Macias RIR
    Hepatology; 2019 Aug; 70(2):547-562. PubMed ID: 30325540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver Expression of Sulphotransferase 2A1 Enzyme Is Impaired in Patients with Primary Sclerosing Cholangitis: Lack of the Response to Enhanced Expression of PXR.
    Wunsch E; Klak M; Wasik U; Milkiewicz M; Blatkiewicz M; Urasinska E; Barbier O; Bielicki D; Bogdanos DP; Elias E; Milkiewicz P
    J Immunol Res; 2015; 2015():571353. PubMed ID: 26504856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis.
    Björnsson E; Kilander A; Olsson R
    Liver; 1999 Dec; 19(6):501-8. PubMed ID: 10661684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders.
    Metzger J; Negm AA; Plentz RR; Weismüller TJ; Wedemeyer J; Karlsen TH; Dakna M; Mullen W; Mischak H; Manns MP; Lankisch TO
    Gut; 2013 Jan; 62(1):122-30. PubMed ID: 22580416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Volatile organic compounds in bile for early diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis: a pilot study.
    Navaneethan U; Parsi MA; Lourdusamy V; Bhatt A; Gutierrez NG; Grove D; Sanaka MR; Hammel JP; Stevens T; Vargo JJ; Dweik RA
    Gastrointest Endosc; 2015 Apr; 81(4):943-9.e1. PubMed ID: 25500329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early and accurate detection of cholangiocarcinoma in patients with primary sclerosing cholangitis by methylation markers in bile.
    Vedeld HM; Grimsrud MM; Andresen K; Pharo HD; von Seth E; Karlsen TH; Honne H; Paulsen V; Färkkilä MA; Bergquist A; Jeanmougin M; Aabakken L; Boberg KM; Folseraas T; Lind GE
    Hepatology; 2022 Jan; 75(1):59-73. PubMed ID: 34435693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum metabolic signatures of primary biliary cirrhosis and primary sclerosing cholangitis.
    Bell LN; Wulff J; Comerford M; Vuppalanchi R; Chalasani N
    Liver Int; 2015 Jan; 35(1):263-74. PubMed ID: 25181933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a scoring system for differentiating IgG4-related sclerosing cholangitis from primary sclerosing cholangitis.
    Moon SH; Kim MH; Lee JK; Baek S; Woo YS; Cho DH; Oh D; Song TJ; Park DH; Lee SS; Seo DW; Lee SK
    J Gastroenterol; 2017 Apr; 52(4):483-493. PubMed ID: 27470434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Novel Insights of Primary Sclerosing Cholangitis and Primary Biliary Cholangitis].
    Ahn DW
    Korean J Gastroenterol; 2020 May; 75(5):246-256. PubMed ID: 32448856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological features of primary sclerosing cholangitis identified by bile proteomic analysis.
    Rupp C; Bode KA; Leopold Y; Sauer P; Gotthardt DN
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1380-1389. PubMed ID: 28943450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis.
    Hultcrantz R; Olsson R; Danielsson A; Järnerot G; Lööf L; Ryden BO; Wahren B; Broomé U
    J Hepatol; 1999 Apr; 30(4):669-73. PubMed ID: 10207809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis.
    Jendrek ST; Gotthardt D; Nitzsche T; Widmann L; Korf T; Michaels MA; Weiss KH; Liaskou E; Vesterhus M; Karlsen TH; Mindorf S; Schemmer P; Bär F; Teegen B; Schröder T; Ehlers M; Hammers CM; Komorowski L; Lehnert H; Fellermann K; Derer S; Hov JR; Sina C
    Gut; 2017 Jan; 66(1):137-144. PubMed ID: 27406039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical clues to suspicion of IgG4-associated sclerosing cholangitis disguised as primary sclerosing cholangitis or hilar cholangiocarcinoma.
    Oh HC; Kim MH; Lee KT; Lee JK; Moon SH; Song TJ; Eum J; Park DH; Lee SS; Seo DW; Lee SK
    J Gastroenterol Hepatol; 2010 Dec; 25(12):1831-7. PubMed ID: 21091993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiopoietin-2 and biliary diseases: elevated serum, but not bile levels are associated with cholangiocarcinoma.
    Voigtländer T; David S; Thamm K; Schlué J; Metzger J; Manns MP; Lankisch TO
    PLoS One; 2014; 9(5):e97046. PubMed ID: 24823366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of serum miRNAs by nano-quantum dots microarray as diagnostic biomarkers for early detection of non-small cell lung cancer.
    Fan L; Qi H; Teng J; Su B; Chen H; Wang C; Xia Q
    Tumour Biol; 2016 Jun; 37(6):7777-84. PubMed ID: 26695145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer.
    Foss KM; Sima C; Ugolini D; Neri M; Allen KE; Weiss GJ
    J Thorac Oncol; 2011 Mar; 6(3):482-8. PubMed ID: 21258252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.